|
KMID : 0620920230550020364
|
|
Experimental & Molecular Medicine
2023 Volume.55 No. 2 p.364 ~ p.376
|
|
|
BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression
|
|
Furong Zeng
Yayun Li
Yu Meng
Huiyan Sun
Yi He
Mingzhu Yin
Xiang Chen
Hwang Joo-Hwan
|
|
|
Abstract
|
|
|
|
Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to combine JQ1 with 240 antitumor drugs from the Food and Drug Administration (FDA)-approved drug library and found that sunitinib synergizes with BET inhibitors in melanoma cells. We further demonstrated that BET inhibitors synergize with sunitinib in melanoma by inducing apoptosis and cell cycle arrest. Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting GDF15 expression. Strikingly, GDF15 is transcriptionally regulated directly by BRD4 or indirectly by the BRD4/IL6/STAT3 axis. Xenograft assays revealed that the combination of BET inhibitors with sunitinib causes melanoma suppression in vivo. Altogether, these findings suggest that BET inhibitor-mediated GDF15 inhibition plays a critical role in enhancing sunitinib sensitivity in melanoma, indicating that BET inhibitors synergize with sunitinib in melanoma.
|
|
|
KEYWORD
|
|
|
Melanoma, Translational research
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|